What was our inspiration for pursuing gamma-delta T cells? Hear from IN8bio’s CEO, William Ho

(3:2)

In8Bio

(13:17)

Why not use traditional CAR-T therapies?

(1:27)

IN8bio's COO, Kate Rochlin, PhD, discusses how we moved into a Phase 2 Clinical Trial so quickly

(53)

IN8bio

(15:30)

Why gamma-delta T cells?

(28:21)

#1 STOCK TO WATCH THIS WEEK! 🚀 MAJOR UPDATES! 💥 HUGE CATALYST!! 😱 IN8bio

(7:52)

Two main issues are often encountered in Cell Therapy

(1:16)

IN8bio progresses its novel approach to cancer therapy with gamma-delta T cell product candidates

(10:32)

#1 STOCK TO WATCH TODAY! 🚀 NEXT GROWTH STORY!? 💥 HUGE CATALYST! 😱 IN8bio

(7:45)

⚡🌡 INAB Stock | Technical Analysis And Predictions | IN8BIO Stock | mesothelioma firm

(1:59)

Lawrence Lamb, Ph.D., at AAI StoryBooth 2024

(5:20)

IPO This Week: Inhibikase (IKT) IN8bio (INAB) \u0026 Natural Order Acquisiton (NOACU): Wk of November 9th

(6:50)

OIS Podcast Episode #291: Developing a Clear Vision for a Clinical Stage Company with Ben Bergo

(27:35)

CRISPR-CLEAR - In-Situ Investigation of Genotype-to... - Luca Pinello - RegSys - ISMB/ECCB 2023

(20:2)

Dr. Doebele on Significant Findings of Entrectinib in Patients With ROS1+ NSCLC

(1:8)

From Thought to Treatment: An Insight into drug development | VIII SBE

(1:32:34)

Duration of Immunotherapy for NSCLC

(5:40)

The fibrinolytic enzymes: lumbrokinase, nattokinase, \u0026 serrapeptase #aspirin

(1:47)

The impact of effective patient communication and on patient trust, compliance, I GBT Microlearning

(2:22)